Tokyo, July 16 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058473) titled 'Benzodiazepines as first-line treatment for status epilepticus in adults: A systematic review and meta-analysis' on July 15.
Study Type:
Others,meta-analysis etc
Primary Sponsor:
Institute - Guideline committee of Japan Resuscitation Council (Neuroresuscitation)
Condition:
Condition - status epilepticus
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To evaluate which benzodiazepine should be used as the first-line treatment for status epilepticus in adults.
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - 1) Randomized controlled trials (RCTs)
2) Studies involving patients with status epilepticus
3) Studies evaluating acute-phase treatment using lorazepam, midazolam, or diazepam, from initial emergency care through intensive care unit (ICU) management
4) English or Japanese
Key exclusion criteria - Conference abstract
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2024 Year 06 Month 18 Day
Anticipated trial start date - 2024 Year 06 Month 18 Day
Last follow-up date - 2024 Year 09 Month 30 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066858
Disclaimer: Curated by HT Syndication.
